Literature DB >> 25078687

Duplication of the A17L locus of vaccinia virus provides an alternate route to rifampin resistance.

Karl J Erlandson1, Catherine A Cotter1, James C Charity1, Craig Martens2, Elizabeth R Fischer2, Stacy M Ricklefs2, Stephen F Porcella2, Bernard Moss3.   

Abstract

UNLABELLED: Specific gene duplications can enable double-stranded DNA viruses to adapt rapidly to environmental pressures despite the low mutation rate of their high-fidelity DNA polymerases. We report on the rapid positive selection of a novel vaccinia virus genomic duplication mutant in the presence of the assembly inhibitor rifampin. Until now, all known rifampin-resistant vaccinia virus isolates have contained missense mutations in the D13L gene, which encodes a capsid-like scaffold protein required for stabilizing membrane curvature during the early stage of virion assembly. Here we describe a second pathway to rifampin resistance involving A17, a membrane protein that binds and anchors D13 to the immature virion. After one round of selection, a rifampin-resistant virus that contained a genomic duplication in the A17L-A21L region was recovered. The mutant had both C-terminally truncated and full-length A17L open reading frames. Expression of the truncated A17 protein was retained when the virus was passaged in the presence of rifampin but was lost in the absence of the drug, suggesting that the duplication decreased general fitness. Both forms of A17 were bound to the virion membrane and associated with D13. Moreover, insertion of an additional truncated or inducible full-length A17L open reading frame into the genome of the wild-type virus was sufficient to confer rifampin resistance. In summary, this report contains the first evidence of an alternate mechanism for resistance of poxviruses to rifampin, indicates a direct relationship between A17 levels and the resistance phenotype, and provides further evidence of the ability of double-stranded DNA viruses to acquire drug resistance through gene duplication. IMPORTANCE: The present study provides the first evidence of a new mechanism of resistance of a poxvirus to the antiviral drug rifampin. In addition, it affirms the importance of the interaction between the D13 scaffold protein and the A17 membrane protein for assembly of virus particles. Resistance to rifampin was linked to a partial duplication of the gene encoding the A17 protein, similar to the resistance to hydroxyurea enabled by duplication of the gene encoding the small subunit of ribonucleotide reductase and of the K3L gene to allow adaptation to the antiviral action of protein kinase R. Gene duplication may provide a way for poxviruses and other DNA viruses with high-fidelity DNA polymerases to adjust rapidly to changes in the environment.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25078687      PMCID: PMC4178789          DOI: 10.1128/JVI.00618-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Regulation of vaccinia virus morphogenesis: phosphorylation of the A14L and A17L membrane proteins and C-terminal truncation of the A17L protein are dependent on the F10L kinase.

Authors:  T Betakova; E J Wolffe; B Moss
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Amplification of the ribonucleotide reductase small subunit gene: analysis of novel joints and the mechanism of gene duplication in vaccinia virus.

Authors:  M B Slabaugh; N A Roseman; C K Mathews
Journal:  Nucleic Acids Res       Date:  1989-09-12       Impact factor: 16.971

3.  Vaccinia virus A17L open reading frame encodes an essential component of nascent viral membranes that is required to initiate morphogenesis.

Authors:  E J Wolffe; D M Moore; P J Peters; B Moss
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

4.  Selection of recombinant vaccinia viruses on the basis of plaque formation.

Authors:  R Blasco; B Moss
Journal:  Gene       Date:  1995-06-09       Impact factor: 3.688

5.  Assembly of vaccinia virus: effects of rifampin on the intracellular distribution of viral protein p65.

Authors:  B Sodeik; G Griffiths; M Ericsson; B Moss; R W Doms
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

6.  The role of a 21-kDa viral membrane protein in the assembly of vaccinia virus from the intermediate compartment.

Authors:  J Krijnse-Locker; S Schleich; D Rodriguez; B Goud; E J Snijder; G Griffiths
Journal:  J Biol Chem       Date:  1996-06-21       Impact factor: 5.157

7.  Vaccinia virus gene A18R encodes an essential DNA helicase.

Authors:  D A Simpson; R C Condit
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

8.  Immature viral envelope formation is interrupted at the same stage by lac operator-mediated repression of the vaccinia virus D13L gene and by the drug rifampicin.

Authors:  Y Zhang; B Moss
Journal:  Virology       Date:  1992-04       Impact factor: 3.616

9.  Vaccinia virus A17L gene product is essential for an early step in virion morphogenesis.

Authors:  D Rodríguez; M Esteban; J R Rodríguez
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

10.  Mutations in ORF D13L and other genetic loci alter the rifampicin phenotype of vaccinia virus.

Authors:  A McNulty-Kowalczyk; E Paoletti
Journal:  Virology       Date:  1993-06       Impact factor: 3.616

View more
  13 in total

Review 1.  Poxvirus membrane biogenesis.

Authors:  Bernard Moss
Journal:  Virology       Date:  2015-02-26       Impact factor: 3.616

2.  Emergence of a Viral RNA Polymerase Variant during Gene Copy Number Amplification Promotes Rapid Evolution of Vaccinia Virus.

Authors:  Kelsey R Cone; Zev N Kronenberg; Mark Yandell; Nels C Elde
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

3.  Structural basis for the inhibition of poxvirus assembly by the antibiotic rifampicin.

Authors:  Damià Garriga; Stephen Headey; Cathy Accurso; Menachem Gunzburg; Martin Scanlon; Fasséli Coulibaly
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-01       Impact factor: 11.205

4.  Experimental Evolution Identifies Vaccinia Virus Mutations in A24R and A35R That Antagonize the Protein Kinase R Pathway and Accompany Collapse of an Extragenic Gene Amplification.

Authors:  Greg Brennan; Jacob O Kitzman; Jay Shendure; Adam P Geballe
Journal:  J Virol       Date:  2015-07-22       Impact factor: 5.103

5.  Gene amplification acts as a molecular foothold to facilitate cross-species adaptation and evasion of multiple antiviral pathways.

Authors:  Shefali Banerjee; Cathy Smith; Adam Geballe; Stefan Rothenburg; Jacob O Kitzman; Greg Brennan
Journal:  bioRxiv       Date:  2022-06-08

6.  Wham: Identifying Structural Variants of Biological Consequence.

Authors:  Zev N Kronenberg; Edward J Osborne; Kelsey R Cone; Brett J Kennedy; Eric T Domyan; Michael D Shapiro; Nels C Elde; Mark Yandell
Journal:  PLoS Comput Biol       Date:  2015-12-01       Impact factor: 4.475

7.  Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus.

Authors:  Zong Sheng Guo; Zuqiang Liu; Magesh Sathaiah; Jiahu Wang; Roshni Ravindranathan; Eun Kim; Shaohua Huang; Thomas W Kenniston; John C Bell; Herbert J Zeh; Lisa H Butterfield; Andrea Gambotto; David L Bartlett
Journal:  Mol Ther Methods Clin Dev       Date:  2017-09-30       Impact factor: 6.698

8.  Long read sequencing reveals poxvirus evolution through rapid homogenization of gene arrays.

Authors:  Thomas A Sasani; Kelsey R Cone; Aaron R Quinlan; Nels C Elde
Journal:  Elife       Date:  2018-08-29       Impact factor: 8.140

9.  Rapid adaptation to human protein kinase R by a unique genomic rearrangement in rhesus cytomegalovirus.

Authors:  Stephanie J Child; Alexander L Greninger; Adam P Geballe
Journal:  PLoS Pathog       Date:  2021-01-26       Impact factor: 6.823

Review 10.  Adaptation by copy number variation in monopartite viruses.

Authors:  Avraham Bayer; Greg Brennan; Adam P Geballe
Journal:  Curr Opin Virol       Date:  2018-07-14       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.